Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.
LLY
BuyPremium GrowerFLAGEli Lilly and Company · Healthcare · United States · $1.0T · Avg Vol: $3.1B/d
Eli Lilly has strong quality Q79 and momentum M80 with a buyback on file, but value at V16 is among the lowest scores in this run and far below the calibrated floor, so stage one fails.
COMPANY DESCRIPTION
Eli Lilly and Company is a global pharmaceutical powerhouse that discovers, develops, manufactures, and markets innovative medicines across key therapeutic areas such as diabetes, oncology, immunology, and neuroscience. Its wide competitive moat is built on a robust R&D pipeline, extensive patent protection for its blockbuster drugs, and a well-established global sales and distribution network. Eli Lilly is a leading innovator, recently achieving significant market success in diabetes and obesity treatments.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 28.5B | 34.1B | 45.0B | 65.2B | 31.7% | 79.7B | 88.2B | 101.8B | 25.0% |
| EPS | 6.57 | 5.83 | 11.80 | 23.07 | 52.0% | 29.80 | 34.98 | 42.95 | 36.5% |
| Shares | 950.2M | 899.4M | 897.5M | 894.8M | -5.8% | 891.7M | — | — | — |
| Debt | 16.2B | 25.2B | 33.6B | 42.5B | 37.8% | 54.9B | — | — | — |
| Equity | 10.6B | 10.8B | 14.3B | 26.5B | 35.6% | — | — | — | — |
| Op CF | 7.6B | 4.2B | 8.8B | 16.8B | 30.4% | 28.1B | — | — | — |
| Inv CF | -3.8B | -7.2B | -9.3B | -11.0B | — | — | — | — | — |
| Fin CF | -5.4B | 3.5B | 1.2B | -2.2B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LLY are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| LLY | Eli Lilly and Company(you) | $1.0T | 77 | Buy |
| JNJ | Johnson & Johnson | $645.9B | 66 | Buy |
| ABBV | AbbVie Inc. | $451.5B | 86 | Strong Buy |
| NVS | Novartis AG | $292.3B | 75 | Buy |
| RO.SW | Roche Holding AG | $360.3B | 86 | Strong Buy |
| MRK | Merck & Co., Inc. | $366.0B | 64 | Hold |
| AZN.ST | AstraZeneca PLC | $252.0B | 71 | Buy |
| GILD | Gilead Sciences, Inc. | $180.6B | 75 | Buy |
| AMGN | Amgen Inc. | $233.8B | 86 | Strong Buy |
| NVO | Novo Nordisk A/S | $201.6B | 89 | Strong Buy |
Peer medians: ROE 2.9% · P/E 24.4x · Gross margin 52.6%